Intravenous lidocaine for refractory pain in patients with pancreatic ductal adenocarcinoma and chronic pancreatitis (LIDOPAN): a multicenter prospective non-randomized pilot study

Simone Augustinus,Matthanja Bieze,Charlotte L. Van Veldhuisen,Marja A. Boermeester,Bert A. Bonsing,Stefan A.W. Bouwense,Marco J. Bruno,Olivier R. Busch,Werner Ten Hoope,Jan-Willem Kallewaard,Henk J. van Kranen,Marieke Niesters,Niels C.J. Schellekens,Monique A.H. Steegers,Rogier P. Voermans,Judith de Vos-Geelen,Johanna W. Wilmink,Jan H.M. Van Zundert,Casper H. van Eijck,Marc G. Besselink,Markus W. Hollmann,for the Dutch Pancreatic Cancer Group and the Dutch Pancreatitis Study Group

DOI: https://doi.org/10.14309/ctg.0000000000000760

2024-08-22

Clinical and Translational Gastroenterology

Abstract:Introduction: Refractory pain is a major clinical problem in patients with pancreatic ductal adenocarcinoma (PDAC) and chronic pancreatitis (CP). New, effective therapies to reduce pain are urgently needed. Intravenous lidocaine is used in clinical practice in patients with PDAC and CP, but its efficacy has not been studied prospectively. Methods: Multicentre prospective non-randomized pilot study including patients with moderate or severe pain (NRS ≥ 4) associated with PDAC or CP in 5 Dutch centers. An intravenous lidocaine bolus of 1.5mg/kg, was followed by continuous infusion at 1.5 mg/kg/hour. The dose was raised every 15 minutes until treatment response (up to a maximum 2mg/kg/hour) and consecutively administered for two hours. Primary outcome was the mean difference in pain severity, pre-infusion and the first day after (Brief Pain Inventory [BPI] scale 1-10). A BPI decrease ≥ 1.3 points was considered clinically relevant. Results: Overall, 30 patients were included, 19 with PDAC (63%) and 11 with CP (37%). The mean difference in BPI at day one was 1.1 (SD±1.3) points for patients with PDAC and 0.5 (SD±1.7) for CP patients. A clinically relevant decrease in BPI on day one was reported in 9/29 patients (31%), this response lasted up to one month. No serious complications were reported, and only three minor complications (vertigo, nausea, tingling of mouth). Treatment with lidocaine did not impact quality of life. Conclusion: Intravenous lidocaine in patients with painful PDAC and CP did not show an overall clinically relevant reduction of pain. However, this pilot study shows that the treatment is feasible in this patient group, and had a positive effect in a third of patients which lasted up to a month with only minor side effects. To prove or exclude the efficacy of intravenous lidocaine, the study should be performed in a study with a greater sample size and less heterogeneous patient group.

gastroenterology & hepatology